68 Results for "

Wnt proteins

" in MedChemExpress (MCE) Product Catalog:
Products (68)

68 Results for "Wnt proteins" in MCE Product Catalog:

315
315 Publications Verification
Cat. No.: HY-10182
CAS No.: 252917-06-9
Purity:  99.43%
Synonyms: CHIR-99021; CT99021
Research Areas:  

Metabolic Disease Cancer

Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .
loading...
    loading...
315
315 Publications Verification
Cat. No.: HY-10182B
CAS No.: 1782235-14-6
Purity:  99.07%
Synonyms: CHIR-99021 trihydrochloride; CT99021 trihydrochloride
Research Areas:  

Cancer

Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy .
loading...
    loading...
315
315 Publications Verification
Cat. No.: HY-10182A
CAS No.: 1797989-42-4
Purity:  99.93%
Synonyms: CHIR-99021 monohydrochloride; CT99021 monohydrochloride
Research Areas:  

Cancer

Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-17439
CAS No.: 55721-31-8
Synonyms: Salinomycin sodium; Sodium salinomycin
Salinomycin sodium salt (Salinomycin sodium), an antibiotic potassium ionophore, is a potent inhibitor of Wnt/β-catenin signaling. Salinomycin sodium salt acts on the Wnt/Fzd/LRP complex, blocks Wnt-induced LRP6 phosphorylation, and causes degradation of the LRP6 protein. Salinomycin sodium salt shows selective activity against human cancer stem cells .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-122816
CAS No.: 854847-61-3
Purity:  98.44%
HLY78, a Lycorine (HY-N0288) derivative, is a potent activator of the Wnt/β-catenin signaling pathway. HLY78 targets the DIX domain of Axin and promotes the Axin-LRP6 (lipoprotein receptor-related protein 6) association, thus promoting LRP6 phosphorylation and Wnt signal transduction. HLY78 can be used for subarachnoid hemorrhage (SAH) research .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-145669
CAS No.: 113411-17-9
Purity:  99.84%
Target:  

Wnt CDK GSK-3

Research Areas:  

Infection Cancer

DIF-3 is an orally active anticancer agent. DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in cells. DIF-3 induces reactive oxygen species (ROS) and autophagy. DIF suppresses the growth of Trypanosoma. cruzi in HT1080 cells. DIF-3 exerts antitumor effects both in vitro and in vivo .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10858
CAS No.: 915759-45-4
Purity:  99.24%
Target:  

sFRP-1 Wnt

Research Areas:  

Cancer

WAY 316606 is an inhibitor of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt. The affinity of WAY-316606 for sFRP-1 is determined using the FP binding assay with IC50 of 0.5 μM .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P99667
CAS No.: 1391727-24-4
Synonyms: OMP-54F28; FZD8-Fc

Target:  

Wnt

Research Areas:  

Cancer

Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10858A
CAS No.: 1781835-02-6
Target:  

sFRP-1 Wnt

Research Areas:  

Cancer

WAY 316606 hydrochloride is an inhibitor of the secreted protein sFRP-1, an endogenous antagonist of the secreted glycoprotein Wnt. The affinity of WAY-316606 for sFRP-1 is determined using the FP binding assay with IC50 of 0.5 μM .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12762
CAS No.: 944328-88-5
Purity:  99.10%
Research Areas:  

Cancer

QS11 is an inhibitor of ARFGAP1 (ADP-ribosylation factor GTPase-activating protein 1), with an EC50 of 1.5 μM. QS11 activates Wnt/β-catenin signaling through an effect on protein trafficking. QS11 inhibits migration of ARFGAP overexpressing breast cancer cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-117163
CAS No.: 2204290-85-5
Purity:  98.93%
Target:  

Wnt β-catenin

Research Areas:  

Cancer

FzM1.8, derives from FzM1, is an allosteric agonist of FZD4 with pEC50 of 6.4. FzM1.8 binds to FZD4 and activates the WNT/β-catenin pathway, by promoting TCF/LEF transcriptional activity in the absence of any WNT ligand. FzM1.8 stabilizes FZD4 with an increased affinity for heterotrimeric G protein and stimulates the release of the Gβγ subunit that in turn activates PI3K .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-129079A
CAS No.: 1445703-64-9
Purity:  99.79%
Research Areas:  

Endocrinology Cancer

TFMB-(S)-2-HG is a potent TET2 inhibitor. TFMB-(S)-2-HG also inhibits the EglN prolyl hydroxylases. TFMB-(S)-2-HG downregulates Wnt3a, β-catenin (intranuclear) protein expression. TFMB-(S)-2-HG inhibits osteogenic differentiation of cells. TFMB-(S)-2-HG has the potential for the research of acute myeloid leukemia (AML) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-124745
CAS No.: 1228280-29-2
Purity:  99.88%
Target:  

MAP4K Wnt Apoptosis

Research Areas:  

Cancer

KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-113283
CAS No.: 451-13-8
Purity:  99.46%
Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as 1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0559
CAS No.: 52659-56-0
Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a Kd value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-117233
CAS No.: 1500080-17-0
Purity:  99.63%
Target:  

β-catenin Wnt

Research Areas:  

Metabolic Disease Cancer

UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI) with a Ki of 1.36 μM . UU-T02 inhibits canonical Wnt signaling and the growth of colorectal cancer cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-112799
CAS No.: 2102672-22-8
Purity:  99.86%
Research Areas:  

Cancer

DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC50 of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-117002
CAS No.: 1030769-75-5
Purity:  98.92%
Target:  

Wnt

Research Areas:  

Cancer

SRI 37892 is a small molecule compound inhibitor of Frizzled protein 7 (Fzd7) with inhibitory activity against cancer cell proliferation (IC50=2μM). SRI 37892 significantly blocks Wnt/Fzd7 signaling. SRI 3789 can be used in the research of developing cancer therapeutic agents .
loading...
    loading...
Cat. No.: HY-147245
CAS No.: 1858179-75-5
Purity:  98.49%
Synonyms: STP1002
Target:  

PARP

Research Areas:  

Cancer

Basroparib (STP1002) is a selective, orally active inhibitor of tankyrase (TNKS1/TNKS2) with IC50 of 29.94 nM and 3.68 nM for TNKS1 and TNKS2, respectively. Basroparib has an IC50 of >10 μM for PARP1. Basroparib binds to TNKS, stabilizes AXIN1/2 proteins, blocks Wnt/β-catenin signaling pathway, inhibits tumor cell proliferation and induces apoptosis, while reducing cancer stem cell properties. Basroparib can be used in colorectal cancer (CRC) studies with KRAS mutations (such as G12V/G12D) to overcome acquired resistance to MEK inhibitors. STP1002 has synergistic antitumor activity with MEK inhibitors .
loading...
    loading...
Cat. No.: HY-10182R
CAS No.: 252917-06-9
Synonyms: CHIR-99021 (Standard); CT99021 (Standard)
Research Areas:  

Cancer

Laduviglusib (Standard) is the analytical standard of Laduviglusib. Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .
loading...
    loading...